KindlyMD(TM) Recognized with Healthcare AI Impact Award 2024
KindlyMD (NASDAQ:KDLY), a patient-first healthcare and healthcare data company, has been recognized with the Healthcare AI Impact Award 2024. The award highlights companies driving improvements in patient care and operational efficiency through AI. KindlyMD was selected from over 400 submissions for its innovative work in leveraging patient data for diagnostics, particularly in exploring the effective use of cannabis in medical treatment.
The company is utilizing machine learning to trace patterns and create models that enhance their care model and improve patient outcomes. Tim Pickett, KindlyMD's founder and CEO, emphasized their commitment to pushing AI boundaries in healthcare to personalize alternative treatments to opioids and help patients make more informed therapeutic decisions.
KindlyMD (NASDAQ:KDLY), una società orientata al paziente nel settore sanitario e nei dati sanitari, è stata riconosciuta con il Healthcare AI Impact Award 2024. Questo premio evidenzia le aziende che migliorano la cura dei pazienti e l'efficienza operativa attraverso l'AI. KindlyMD è stata selezionata tra oltre 400 candidature per il suo lavoro innovativo nell'utilizzo dei dati dei pazienti per la diagnostica, in particolare nell'esplorazione dell'uso efficace della cannabis nel trattamento medico.
L'azienda sta utilizzando l'apprendimento automatico per tracciare schemi e creare modelli che migliorano il loro modello di cura e ottimizzano i risultati per i pazienti. Tim Pickett, fondatore e CEO di KindlyMD, ha sottolineato il loro impegno per spingere i confini dell'AI nella sanità al fine di personalizzare i trattamenti alternativi agli oppioidi e aiutare i pazienti a prendere decisioni terapeutiche più informate.
KindlyMD (NASDAQ:KDLY), una empresa orientada al paciente en el sector de la salud y datos de salud, ha sido reconocida con el Healthcare AI Impact Award 2024. Este premio destaca a las empresas que impulsan mejoras en la atención al paciente y la eficiencia operativa a través de la IA. KindlyMD fue seleccionada entre más de 400 propuestas por su trabajo innovador en el aprovechamiento de los datos del paciente para diagnósticos, particularmente en el uso efectivo del cannabis en tratamientos médicos.
La empresa está utilizando aprendizaje automático para rastrear patrones y crear modelos que mejoran su modelo de atención y los resultados para los pacientes. Tim Pickett, fundador y CEO de KindlyMD, enfatizó su compromiso de empujar los límites de la IA en la salud para personalizar tratamientos alternativos a los opioides y ayudar a los pacientes a tomar decisiones terapéuticas más informadas.
KindlyMD (NASDAQ:KDLY)는 환자 중심의 헬스케어 및 헬스케어 데이터 회사로, 2024 헬스케어 AI 임팩트 어워드를 수상했습니다. 이 상은 AI를 통해 환자 치료와 운영 효율성을 개선하는 기업을 강조합니다. KindlyMD는 진단을 위한 환자 데이터 활용의 혁신적인 작업으로 400개 이상의 제출물 중에서 선정되었으며, 특히 의료 치료에서 대마초의 효과적인 사용을 탐구하고 있습니다.
회사는 패턴을 추적하고 모델을 생성하기 위해 기계 학습을 활용하여 치료 모델을 개선하고 환자 결과를 향상시키고 있습니다. KindlyMD의 창립자이자 CEO인 Tim Pickett는 AI의 경계를 넓히고 오피오이드 대체 치료를 개인화하며 환자가 보다 정보에 기반한 치료 결정을 내릴 수 있도록 돕겠다는 약속을 강조했습니다.
KindlyMD (NASDAQ:KDLY), une entreprise axée sur le patient dans le domaine de la santé et des données sanitaires, a été reconnue avec le Healthcare AI Impact Award 2024. Ce prix met en avant les entreprises qui améliorent les soins aux patients et l'efficacité opérationnelle grâce à l'IA. KindlyMD a été sélectionnée parmi plus de 400 candidatures pour son travail innovant sur l'utilisation des données des patients pour le diagnostic, en particulier pour explorer l'utilisation efficace du cannabis dans le traitement médical.
L'entreprise utilise l'apprentissage automatique pour tracer des schémas et créer des modèles qui améliorent leur modèle de soins et optimisent les résultats pour les patients. Tim Pickett, fondateur et PDG de KindlyMD, a souligné leur engagement à repousser les limites de l'IA en matière de santé afin de personnaliser les traitements alternatifs aux opioïdes et d'aider les patients à prendre des décisions thérapeutiques plus éclairées.
KindlyMD (NASDAQ:KDLY), ein patientenorientiertes Gesundheits- und Gesundheitsdatenunternehmen, wurde mit dem Healthcare AI Impact Award 2024 ausgezeichnet. Der Preis hebt Unternehmen hervor, die Verbesserungen in der Patientenversorgung und betrieblichen Effizienz durch KI vorantreiben. KindlyMD wurde aus über 400 Einreichungen für seine innovativen Arbeiten zur Nutzung von Patientendaten für Diagnosen ausgewählt, insbesondere zur Erforschung der effektiven Nutzung von Cannabis in der medizinischen Behandlung.
Das Unternehmen nutzt Machine Learning, um Muster zu erkennen und Modelle zu erstellen, die ihr Versorgungsmodell verbessern und die Patienten Ergebnisse optimieren. Tim Pickett, Gründer und CEO von KindlyMD, betonte ihr Engagement, die Grenzen der KI im Gesundheitswesen zu verschieben, um alternative Behandlungen zu Opioiden zu personalisieren und den Patienten zu helfen, fundiertere therapeutische Entscheidungen zu treffen.
- Recognition with Healthcare AI Impact Award 2024 out of 400+ submissions
- Innovative use of AI in leveraging patient data for diagnostics
- Expanding knowledge on effective medical use of cannabis
- Developing machine learning models to enhance care and improve patient outcomes
- Potential for better personalization of alternative treatments to opioids
- None.
SALT LAKE CITY, UT / ACCESSWIRE / September 12, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced it has been recognized as one of the winners of the Healthcare AI Impact Award 2024. This award spotlights the most forward-thinking companies in healthcare, driving real improvements in patient care and operational efficiency through the use of artificial intelligence.
Out of over 400 submissions, KindlyMD was selected for its innovative work with AI in leveraging patient data in diagnostics. Utilizing preliminary data analysis efforts from various data repositories designed to extract all viable data from their enterprise systems, KindlyMD is expanding the knowledge of how cannabis may be effectively used in medical treatment, leading to better patient outcomes and informed therapeutic decisions. Using data in machine learning efforts, the Company's data informatics personnel are tracing patterns and creating models that will enhance and validate their model of care to improve the lives of patients.
"We're honored that we have been recognized for our work in AI-driven patient diagnostics," said Tim Pickett, PA-C, KindlyMD founder and CEO. "This award is a great acknowledgment of our team's hard work and our commitment to pushing the boundaries of AI in healthcare to improve patient outcomes and better personalize alternative treatments to opioids and other harsh prescriptions. KindlyMD is dedicated to keep driving innovation that makes a real difference for patients by helping them make more informed therapeutic decisions."
You can see the full list of this year's winners at www.modernleader.io/healthcare-awards and in the October issue of Modern Leader's printed edition.
About KindlyMD
KindlyMD™ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers, including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including, but not limited to, the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com
SOURCE: KindlyMD, Inc
View the original press release on accesswire.com
FAQ
What award did KindlyMD (KDLY) receive in 2024?
How is KindlyMD (KDLY) using AI in healthcare?
What is KindlyMD's (KDLY) approach to alternative treatments?
How many submissions were there for the Healthcare AI Impact Award 2024?
